As medical science advances, so does our understanding of drug safety and the need for vigilance when it comes to monitoring its usage. In recent years, pharmacovigilance has gained significant attention and importance due to the growing complexity of drug therapies, the emergence of new medicines, and the increased scrutiny of regulatory agencies. This has led to a greater emphasis on monitoring the safety profiles of pharmaceutical products throughout their lifecycle, from pre-marketing clinical trials to post-marketing surveillance.
The need for effective pharmacovigilance systems becomes even more crucial as the global population continues to expand, resulting in an increased consumption of medications. Adverse drug reactions (ADRs) can have severe consequences, leading to hospitalizations, prolonged treatments, and in some cases, even fatalities. Therefore, it is imperative to enhance our understanding of ADRs, identify potential risks, and implement appropriate risk mitigation strategies. To efficiently address these challenges, collaboration between international regulatory bodies, healthcare providers, and patients is essential. With a strong focus on patient safety as well as public health and by creating an interconnected network of experts from around the world who are dedicated to advancing our understanding of drug safety and pharmacovigilance, we can create a robust system.